Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,000,576 papers from all fields of science
Search
Sign In
Create Free Account
AM-0715
Known as:
AM 0715
, AM 715
, AM0715
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Norfloxacin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
[Evaluation of norfloxacin in the pediatric field. Pediatric Study Group for Norfloxacin].
R. Fujii
,
H. Meguro
,
+7 authors
H. Ichihashi
The Japanese Journal of Antibiotics
1990
Corpus ID: 25421981
Norfloxacin (NFLX, AM-715), a new quinolone antibiotic agent, was evaluated clinically and bacteriologically for its efficacy and…
Expand
Highly Cited
1983
Highly Cited
1983
Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans
J. Shimada
,
T. Yamaji
,
Y. Ueda
,
H. Uchida
,
H. Kusajima
,
T. Irikura
Antimicrobial Agents and Chemotherapy
1983
Corpus ID: 382883
The mechanisms of the renal excretion of AM-715, a synthetic antimicrobial agent, were studied in rabbits, dogs, and humans. In…
Expand
Highly Cited
1983
Highly Cited
1983
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens
D. Shungu
,
E. Weinberg
,
H. Gadebusch
Antimicrobial Agents and Chemotherapy
1983
Corpus ID: 31904987
A comparison was made of the in vitro activities of norfloxacin and of nine other orally administered antibacterial agents…
Expand
1983
1983
Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715)
D. Shungu
,
E. Weinberg
,
H. Gadebusch
Antimicrobial Agents and Chemotherapy
1983
Corpus ID: 42889249
Norfloxacin is a new orally absorbed quinoline derivative structurally related to nalidixic acid but showing an expanded…
Expand
1983
1983
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
R. Jones
,
A. Barry
Diagnostic microbiology and infectious disease
1983
Corpus ID: 30310049
1983
1983
In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid
P. Shah
,
M. Ottrad
,
W. Stille
European Journal of Clinical Microbiology
1983
Corpus ID: 39863788
1. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a…
Expand
1982
1982
[Pharmaceutical studies on hydrates of AM-715. Physical characteristics and intestinal absorption].
R. Yuasa
,
J. Imai
,
H. Morikawa
,
H. Kusajima
,
H. Uchida
,
T. Irikura
Yakugaku zasshi : Journal of the Pharmaceutical…
1982
Corpus ID: 45674452
1981
1981
Comparative Activities of AM-715 and Pipemidic and Nalidixic Acids Against Experimentally Induced Systemic and Urinary Tract Infections
K. Hirai
,
A. Ito
,
+4 authors
S. Mitsuhashi
Antimicrobial Agents and Chemotherapy
1981
Corpus ID: 11055656
Dose for dose, AM-715 was at least five times as active as pipemidic acid and nalidixic acid against systemic and urinary bladder…
Expand
1981
1981
Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae
M. Y. Khan
,
Y. Siddiqui
,
R. Gruninger
Antimicrobial Agents and Chemotherapy
1981
Corpus ID: 28306380
The in vitro activity of a new ora antimicrobial agent, Mk-0366 (AM-715), was compared with those of rosoxacin, ampicillin…
Expand
Highly Cited
1980
Highly Cited
1980
In Vitro Antibacterial Activity of AM-715, a New Nalidixic Acid Analog
A. Ito
,
K. Hirai
,
+4 authors
S. Mitsuhashi
Antimicrobial Agents and Chemotherapy
1980
Corpus ID: 42843247
AM-715 [1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid] is a new nalidixic acid analog. AM-715…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE